Video

New Delivery Option for Ketamine

How can new formulations of ketamine impact patient care?

Jeffrey Becker, MD, discusses new formulations of ketamine for subcutaneous delivery and how ketamine works.

Dr Becker is cofounder and Chief Scientific Officer at Bexson Biomedical, Inc.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
© 2024 MJH Life Sciences

All rights reserved.